欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01477 欧康维视生物-B

交易中 03-06 15:43:22

6.930

+0.230

+3.43%

最高6.990	最低6.680	成交量32.45万
今开6.710	昨收6.700	日振幅4.63%
总市值56.48亿	流通市值56.48亿	总股本8.15亿
成交额224.50万	换手率0.04%	流通股本8.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":6.93,"timestamp":1772782846284,"preClose":6.7,"halted":0,"volume":324500,"delay":0,"changeRate":0.034328358208955155,"floatShares":815000000,"shares":815000000,"eps":-0.392324,"marketStatus":"交易中","change":0.23,"latestTime":"03-06 15:43:22","open":6.71,"high":6.99,"low":6.68,"amount":2244980,"amplitude":0.046269,"askPrice":6.93,"askSize":11500,"bidPrice":6.91,"bidSize":15500,"shortable":3,"etf":0,"ttmEps":-0.335,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1772784600000},"marketStatusCode":2,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":6.7,"openAndCloseTimeList":[[1772760600000,1772769600000],[1772773200000,1772784000000]],"volumeRatio":0.277309,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477","defaultTab":"news","newsList":[{"id":"2617850659","title":"汉方制药IPO：核心产品增长触顶新药布局难解近渴 实控人兄弟100%控股递表前大额派息","url":"https://stock-news.laohu8.com/highlight/detail?id=2617850659","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617850659?lang=zh_cn&edition=full","pubTime":"2026-03-06 10:37","pubTimestamp":1772764620,"startTime":"0","endTime":"0","summary":"　　生物医药产业赴港上市潮持续升温，成为资本市场上的热门风景线。近日，手握外用中成药领域唯一获批的处方涂剂的山东汉方制药股份有限公司也加入战局，拟登陆港交所主板。公司聚焦皮肤及黏膜疾病治疗领域，凭借独家保护品种创下超过80%的高毛利率，展现出较强的盈利韧性。　　此外值得关注的是，汉方制药在IPO前两度大额派息。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-03-06/doc-inhpzeqt9371507.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","01477","BK1191"],"gpt_icon":0},{"id":"2617500116","title":"信达生物制药2026年2月股份变动月报","url":"https://stock-news.laohu8.com/highlight/detail?id=2617500116","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617500116?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:13","pubTimestamp":1772720026,"startTime":"0","endTime":"0","summary":"金吾财讯|信达生物制药于2026年3月5日提交了2026年2月的股份变动月报表。在股份期权方面，公司的首次公开发售前股份奖励计划、首次公开发售后雇员持股计划以及2024年股份计划均未有新的股份发行或库存股份转让。同时，公司在该月内也未进行任何股份回购、股权激励计划的行权或其他导致已发行股份或库存股份变动的操作。综上所述，信达生物制药在2026年2月的股份结构保持稳定，未发生任何变动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305222756a4503acf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305222756a4503acf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","01477","BK1583","LU2097828557.USD","LU2097828714.EUR","LU2097828474.EUR","BK1589","LU2328871848.SGD","BK1574","LU1969619763.USD","LU2097828631.EUR","LU2097828805.USD","BK1191","01801","LU0455707207.USD","LU0502904849.HKD","LU2242644610.SGD","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"1159096528","title":"欧康维视生物-B（01477）2026年2月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1159096528","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159096528?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:35","pubTimestamp":1772699742,"startTime":"0","endTime":"0","summary":"欧康维视生物-B于2026年3月5日发布截至2026年2月28日的月度股份变动报告。公告显示，公司注册股本仍为5,000,000,000股，面值每股USD 0.00001，注册股本总额USD 50,000，与上月持平。在股份期权及股权激励方面，2018年采纳的员工购股权计划结存期权数量为13,317,816份，无新增行使或取消。2021年购股权计划月内失效3,520份期权，结存期末为37,591,614份期权，尚未行使的期权未发生新股发行。公司表示，截至本月末整体已发行股本及公眾持股量符合香港联交所相关规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477"],"gpt_icon":0},{"id":"2617573087","title":"国内AI制药再迎来该“AI＋RNA”小分子创新药完成头例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2617573087","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617573087?lang=zh_cn&edition=full","pubTime":"2026-03-05 09:48","pubTimestamp":1772675280,"startTime":"0","endTime":"0","summary":"近年来AI制药兴起，全球AI制药企业超350家，国内不少于100家。3月2日，晶泰科技孵化企业ReviR宣布，其小分子药物管线RTX-117完成头例受试者给药，正式进入临床开发阶段，有望为腓骨肌萎缩症、白质消融性白质脑病等神经系统疾病患者提供治疗方案。RTX-117结合晶泰科技AI+机器人药物研发平台与ReviR对RNA生物学的理解，通过抑制异常激活的ISR通路，恢复mRNA正常翻译，从分子根源治疗疾病，未来有望拓展至更多适应症。晶泰科技正强化其优势与商业化价值，先后与多家企业达成合作，东阳光药与其成立合资公司，构建长期、深度绑定的技术共生关系。有机构表示，AI技术正改变新药研发格局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305100816a44d84db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305100816a44d84db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01477","BK1191","06887"],"gpt_icon":0},{"id":"2616510655","title":"每日卖空追踪 | 歌礼制药-B 03月04日卖空量成交30.7万股，卖空比例为9.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616510655","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616510655?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:30","pubTimestamp":1772613023,"startTime":"0","endTime":"0","summary":"歌礼制药-B北京时间03月04日，跌1.53%，卖空量成交30.7万股，较上一交易日减少6.97%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163306a44a6c52&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163306a44a6c52&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1515","01477","BK1574","BK1191","01672"],"gpt_icon":0},{"id":"2616869015","title":"中国药企移植领域最大规模对外授权交易！中生制药官宣15亿美元合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2616869015","media":"澎湃新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616869015?lang=zh_cn&edition=full","pubTime":"2026-03-04 14:08","pubTimestamp":1772604507,"startTime":"0","endTime":"0","summary":"春节后，中国创新药的BD（业务拓展）热度不减，仅3月4日上午就有两笔BD交易官宣。3月4日，港股制药龙头中国生物制药（01177.HK）与全球跨国制药巨头赛诺菲联合宣布，双方就全球首创JAK/ROCK双靶点抑制剂罗伐昔替尼，达成独家全球许可协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603043661604737.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603043661604737.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01477","BK1191","BK1574"],"gpt_icon":0},{"id":"2616071843","title":"汉方制药，豪赌一瓶药水","url":"https://stock-news.laohu8.com/highlight/detail?id=2616071843","media":"斑马消费","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616071843?lang=zh_cn&edition=full","pubTime":"2026-03-04 07:53","pubTimestamp":1772581980,"startTime":"0","endTime":"0","summary":"拥有技术和政策保护双壁垒，汉方制药仅靠一瓶药水，缔造了一个行业奇迹。日前，公司携带这瓶药水奔赴港股。2016年，国家认定该产品为二级中药保护品种，汉方制药因此享有市场独占权，其他药企禁止生产同类产品。跨界化妆品汉方制药脆弱的收入结构、4年后大单品政策保护大限，问题相当棘手。家族企业汉方制药是一家典型的家族企业。产品热销之后，为汉方制药积累了丰厚的利润，秦氏兄弟获益匪浅。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI0MDY2ODM2MQ==&mid=2247521665&idx=2&sn=60788eada704172e1636460ba1e0f71b&chksm=e8c0ae8c7b1146fe9f1412de78af18f1eb021d94ba8f36d7b1db8ce0af3634a78f506b656eb5&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["01477","BK1191","BK1574"],"gpt_icon":0},{"id":"2616732477","title":"阿斯彭制药计划今年三季度前在加拿大推出司美格鲁肽仿制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2616732477","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616732477?lang=zh_cn&edition=full","pubTime":"2026-03-03 23:51","pubTimestamp":1772553060,"startTime":"0","endTime":"0","summary":"南非制药集团阿斯彭制药首席执行官周二表示，公司开发的诺和诺德热门降糖药Ozempic 仿制药，有望在今年第二季度或第三季度在加拿大获得注册批准。　　“我们正在收到监管机构的反馈。按目前情况判断，我们有望在今年二季度末或三季度—— 也就是 5 月至 9 月之间 —— 获得注册批准。”斯蒂芬萨德对路透社表示。　　今年 1 月，诺和诺德用于糖尿病治疗的司美格鲁肽专利在加拿大到期，阿斯彭希望成为加拿大首批推出 Ozempic 仿制药的企业之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-03/doc-inhptvfa7267205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","01477","BK1574"],"gpt_icon":0},{"id":"2616263053","title":"欧康维视生物-B盘中异动 下午盘快速下挫5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616263053","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616263053?lang=zh_cn&edition=full","pubTime":"2026-03-03 14:20","pubTimestamp":1772518857,"startTime":"0","endTime":"0","summary":"2026年03月03日下午盘14时20分，欧康维视生物-B股票出现异动，股价急速下挫5.06%。截至发稿，该股报6.570港元/股，成交量76.9万股，换手率0.09%，振幅6.36%。欧康维视生物-B股票所在的生物技术行业中，整体跌幅为3.89%。欧康维视生物-B公司简介：欧康维视生物是一家主要从事眼科药物的研发和商业化的公司。该公司主要在中国国内市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030314205797a7c9fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030314205797a7c9fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","BK1574","BK1191"],"gpt_icon":0},{"id":"2616145339","title":"每日卖空追踪 | 欧康维视生物-B 03月02日卖空量成交8.6万股，卖空比例为3.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616145339","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616145339?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:30","pubTimestamp":1772440224,"startTime":"0","endTime":"0","summary":"欧康维视生物-B北京时间03月02日，跌8.22%，卖空量成交8.6万股，较上一交易日减少76.5%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302163315a730c57f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302163315a730c57f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1574","01477"],"gpt_icon":0},{"id":"2616833947","title":"歌礼制药-B03月02日主力净流出59.3万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2616833947","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616833947?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:15","pubTimestamp":1772439327,"startTime":"0","endTime":"0","summary":"03月02日, 歌礼制药-B股价跌3.17%，报收15.26元，成交金额2504.9万元，换手率0.15%，振幅4.19%，量比0.75。歌礼制药-B今日主力资金净流出59.3万元，上一交易日主力净流出0万元。该股近5个交易日下跌9.60%，主力资金累计净流出313.9万元；近20日主力资金累计净流入2861.2万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302161650a730aeb3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302161650a730aeb3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","01672","01477","BK1191","BK1515"],"gpt_icon":0},{"id":"2616339107","title":"欧康维视生物-B盘中异动 早盘股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616339107","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616339107?lang=zh_cn&edition=full","pubTime":"2026-03-02 09:42","pubTimestamp":1772415745,"startTime":"0","endTime":"0","summary":"2026年03月02日早盘09时42分，欧康维视生物-B股票出现波动，股价急速下跌5.04%。截至发稿，该股报7.160港元/股，成交量5.5万股，换手率0.01%，振幅5.70%。欧康维视生物-B股票所在的生物技术行业中，整体跌幅为1.90%。其相关个股中，正大企业国际、歌礼制药-B、愉悦集团涨幅较大，振幅较大的相关个股有MIRXES-B、康诺亚-B、帝王国际投资，振幅分别为7.19%、6.52%、6.03%。欧康维视生物-B公司简介：欧康维视生物是一家主要从事眼科药物的研发和商业化的公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302094225954283a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302094225954283a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1191","01477"],"gpt_icon":0},{"id":"2614813254","title":"新股前瞻｜年入8亿九成靠一瓶涂剂 汉方制药闯关港股面临“悬崖考验”","url":"https://stock-news.laohu8.com/highlight/detail?id=2614813254","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614813254?lang=zh_cn&edition=full","pubTime":"2026-02-28 16:38","pubTimestamp":1772267929,"startTime":"0","endTime":"0","summary":"凭借一瓶涂剂年入8亿，山东汉方制药正在叩响港股的大门，中泰国际担任独家保荐人。财务数据显示，汉方制药的收入从2023年的10.53亿元下滑至2024年的9.92亿元，同比降幅约12%。此外，作为拥有独家品种的中药企业，汉方制药展现了极强的上游议价能力。同期一般及行政开支同比大增38.9%，进一步挤压了利润空间。2025年前九个月，核心产品“复方黄柏液涂剂”贡献收入8.00亿元，占总收入比重高达99.7%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408617.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VT","BK4585","BK4588","BK1574","VXUS","01477","BK1191"],"gpt_icon":0},{"id":"2614836531","title":"每日卖空追踪 | 欧康维视生物-B 02月27日卖空量成交5.25万股，卖空比例为7.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614836531","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614836531?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:30","pubTimestamp":1772181022,"startTime":"0","endTime":"0","summary":"欧康维视生物-B北京时间02月27日，涨6.2%，卖空量成交5.25万股，较上一交易日减少78.08%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227163247a436772a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227163247a436772a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01477","BK1191"],"gpt_icon":0},{"id":"2614283653","title":"欧康维视生物-B02月27日获主力加仓6.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614283653","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614283653?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:15","pubTimestamp":1772180142,"startTime":"0","endTime":"0","summary":"02月27日, 欧康维视生物-B股价涨6.20%，报收7.54元，成交金额486.3万元，换手率0.08%，振幅6.76%，量比0.75。欧康维视生物-B今日主力资金净流入6.3万元，上一交易日主力净流入75.9万元。该股近5个交易日上涨2.45%，主力资金累计净流出52.8万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出666.6万元，其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227161840a4cefc7d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227161840a4cefc7d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","01477","BK1574"],"gpt_icon":0},{"id":"2614489200","title":"复方黄柏液涂剂独家护航，秦氏兄弟70岁仍在掌舵，家族控股企业汉方制药赴港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2614489200","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614489200?lang=zh_cn&edition=full","pubTime":"2026-02-26 19:24","pubTimestamp":1772105052,"startTime":"0","endTime":"0","summary":"公司核心产品为复方黄柏液涂剂，该产品是目前国内唯一获批的处方中成药涂剂，被认定为国家二级中药保护品种，依法享有独家生产与市场保护权，不存在直接同类竞争产品。同时，公司股权结构高度集中，由秦文基、秦银基兄弟合计全资持股。其中，秦文基、秦银基、秦淑芬女士为兄弟姐妹关系，其中，秦文基为哥哥，秦文基现年已70岁，仍担任公司董事长，秦银基现年63岁，为公司总经理。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1772104246818528467","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1191","BK1574","01477"],"gpt_icon":0},{"id":"2614308246","title":"诺华制药拟在德州新建放射性配体疗法生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2614308246","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614308246?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:02","pubTimestamp":1772024578,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0211331839.USD","BK4532","BK4588","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4578","BK1574","BK1191","BK4585","01477","IE0002141913.USD","LU0208291251.USD","NVS","BK4007","IE00B4R5TH58.HKD","LU0070302665.USD","LU0320765489.SGD"],"gpt_icon":0},{"id":"2614081119","title":"兴齐眼药：公司专注于眼科制药领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2614081119","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614081119?lang=zh_cn&edition=full","pubTime":"2026-02-25 20:05","pubTimestamp":1772021123,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药(300573)02月25日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘你好！请问贵公司如何看待中国新生儿快速下降?对未来公司业绩可能带来的影响?兴齐眼药回复：尊敬的投资者您好！公司将持续关注行业及外部宏观环境的变化。公司专注于眼科制药领域，产品覆盖各年龄段人群，未来将持续聚焦主业，不断提升核心竞争力与经营质量，具体经营情况请以公告信息为准，感谢您的关注。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260225/32027104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01477","300573","BK0239","BK0177","BK1191","BK1574"],"gpt_icon":0},{"id":"2614819650","title":"新股消息 | 汉方制药递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2614819650","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614819650?lang=zh_cn&edition=full","pubTime":"2026-02-25 20:02","pubTimestamp":1772020967,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所2月25日披露，山东汉方制药股份有限公司(简称：汉方制药)向港交所主板递交上市申请书，中泰国际为其独家保荐人。招股书显示，汉方制药是一家从事中医药产品的生产、销售与研发的综合制药公司。公司专注于皮肤及黏膜疾病治疗领域，善于将传统中医智慧与现代医药科学相融合。根据弗若斯特沙利文的资料，按2024年销售收入计，复方黄柏液涂剂在中国外用中成药市场排名第四，占据1.1%的市场份额。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01477","BK1574","HEXmain"],"gpt_icon":0},{"id":"2614124036","title":"每日卖空追踪 | 欧康维视生物-B 02月25日卖空量成交3.05万股，卖空比例为6.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614124036","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614124036?lang=zh_cn&edition=full","pubTime":"2026-02-25 16:30","pubTimestamp":1772008224,"startTime":"0","endTime":"0","summary":"欧康维视生物-B北京时间02月25日，跌0.69%，卖空量成交3.05万股，较上一交易日减少86.83%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225163250a4c673b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225163250a4c673b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1574","01477"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":-0.0563},{"period":"1month","weight":-0.0759},{"period":"3month","weight":-0.1928},{"period":"6month","weight":-0.3619},{"period":"1year","weight":0.4378},{"period":"ytd","weight":-0.0946}],"compareEarnings":[{"period":"1week","weight":-0.0402},{"period":"1month","weight":-0.0564},{"period":"3month","weight":-0.0293},{"period":"6month","weight":-0.0038},{"period":"1year","weight":0.0732},{"period":"ytd","weight":-0.0121}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科药物的研发和商业化的公司。该公司产品主要包括OT-401“优施莹”氟轻松玻璃体内植入剂、OT-702“博优景”阿柏西普眼内注射溶液、OT-402“维速达尔”注射用维替泊芬、OT-204“欧沁”玻璃酸钠滴眼液及OT-305“贝特舒”盐酸倍他洛尔滴眼液等。该公司产品主要用于治疗葡萄膜炎、眼底疾病、屈光矫正、干眼症（DED）、青光眼及角结膜炎等各种眼前及眼后段疾病。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.097698},{"month":2,"riseRate":0.5,"avgChangeRate":-0.037557},{"month":3,"riseRate":0.5,"avgChangeRate":0.029858},{"month":4,"riseRate":0.4,"avgChangeRate":0.017956},{"month":5,"riseRate":0.6,"avgChangeRate":0.137077},{"month":6,"riseRate":0.8,"avgChangeRate":0.129408},{"month":7,"riseRate":0.4,"avgChangeRate":-0.027707},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.064893},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.082685},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.121217},{"month":11,"riseRate":0.333333,"avgChangeRate":0.004503},{"month":12,"riseRate":0.5,"avgChangeRate":0.058088}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}